Direct answer
There is no FDA-approved DSIP dosage chart or standard sleep protocol
DSIP, also called delta sleep-inducing peptide or Emideltide, is a nine-amino-acid investigational peptide discussed in sleep and neuroendocrine research. It does not have an FDA-approved finished-drug label for insomnia, sleep quality, recovery, anxiety, withdrawal, or longevity. Online pages may present an exact amount, bedtime window, escalation plan, cycle length, or repeat schedule as routine care, but those numbers do not establish product identity, effectiveness, safety, or fit for a particular patient.
- Do not treat a search snippet, forum post, influencer video, clinic blog, seller chart, certificate of analysis, or research-vial label as prescribing information.
- The amount printed on a vial is package content—not a patient-specific dose, concentration check, route decision, or proof of sterility.
- Words such as “microdose,” “starter dose,” “standard protocol,” or “natural sleep peptide” do not create a proven safety threshold.
Human evidence boundary
Old intravenous studies do not validate modern seller protocols
A double-blind study in 16 people with chronic insomnia evaluated short-term intravenous DSIP and reported weak objective signals without convincing overall therapeutic benefit. A separate 1981 report involved six people with disturbed sleep. A 2006 review concluded that the proposed relationship between DSIP and sleep remained poorly documented and biologically unresolved. These publications are useful evidence limits, not a modern dosing program: they do not establish a labeled therapeutic range, subcutaneous or nasal conversion, titration schedule, interaction profile, pregnancy safety, or long-term outcomes.
- Do not convert an intravenous research method into a subcutaneous, nasal, oral, or bedtime protocol.
- Small studies cannot reliably identify uncommon harms, define who benefits, or show that a marketed product matches the material used in research.
- A mechanism, animal experiment, laboratory concentration, or anecdote cannot supply the missing human dose-response and product-quality evidence.
Product and route identity
Injection, nasal, oral, and research-use DSIP cannot share one chart
The name DSIP does not identify a complete medication. Ingredient form, route, concentration, excipients, sterility, container, storage, beyond-use date, pharmacy controls, and patient health context can all change exposure and risk. A compounded DSIP injection is not an FDA-approved finished drug product. A nasal spray or oral product does not inherit evidence from an intravenous study, and a research-use vial should not be treated as medication for people.
- Do not use a volume-only or “units” chart without the patient-specific prescription label and direct pharmacy instructions; concentrations may differ.
- Do not copy reconstitution, injection, timing, cycling, missed-dose, or route-conversion instructions from another product or seller.
- Confirm the licensed prescriber, dispensing pharmacy, exact ingredient, route, concentration, lot, storage, beyond-use date, and adverse-event contact.
Sleep and safety review
The diagnosis and medication list come before any peptide discussion
Difficulty falling asleep, repeated awakenings, early waking, nightmares, non-restorative sleep, and dangerous daytime sleepiness can have different causes. Sleep apnea, depression, anxiety, bipolar symptoms, substance use, restless legs, pain, reflux, thyroid disease, anemia, pregnancy or menopause, shift work, and medicine effects may require targeted care. Adding or escalating DSIP from a chart can delay sleep testing, mental-health care, medication review, or treatment of another condition.
- Review alcohol, cannabis, opioids, benzodiazepines, Z-drugs, sedating antihistamines, antidepressants, antipsychotics, seizure medicines, muscle relaxants, melatonin, valerian, magnesium blends, and other peptides or supplements.
- Do not drive, operate equipment, or perform safety-sensitive work if a new product is followed by grogginess, dizziness, slowed thinking, poor coordination, or unexpected sleepiness.
- Trouble breathing, facial or throat swelling, fainting, seizure, severe confusion, suicidal thoughts, inability to stay awake safely, fever, or rapidly worsening injection-site redness or pain needs prompt medical evaluation—not a chart adjustment.
FDA policy and buyer safety
The July 2026 PCAC agenda did not create DSIP dosing guidance
FDA and the Federal Register scheduled Emideltide/DSIP free base and acetate for discussion at the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting in the section 503A bulks-list process. Those dates have passed as of this Pacific-time review, but an agenda listing or advisory-committee discussion is not FDA approval, a finished-drug label, a patient dosing recommendation, proof of safety or effectiveness, or permission for no-prescription sales. This page does not infer a final FDA determination from the meeting calendar; patients and clinicians should verify any later policy action in current official FDA records.
- Reject “FDA-approved DSIP dose,” “July-approved protocol,” “PCAC-approved cycle,” and “legal research peptide for human use” claims unless a current official FDA source supports the exact statement.
- A committee process cannot validate seller calculators, vial math, injection instructions, sleep stacks, or guaranteed outcomes.
- Compounded medicines are not FDA-approved finished drug products; legitimate care still requires an appropriate prescription and an identified licensed pharmacy.